BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesClinical readout

NBIP-'2118 targets a new, non-incretin mechanism for weight loss with lean mass preservation SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of

Open original release

Related news

VKTXViking Therapeutics2026-06-24 11:05 EST

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

TSHATaysha Gene Therapies2026-06-22 12:00 EST

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

NBIXNeurocrine Biosciences2026-06-03 12:30 EST

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

NBIXNeurocrine Biosciences2026-05-01 20:05 EST

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

HRMYHarmony Biosciences2026-04-16 12:05 EST

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

KTTAPasithea Therapeutics2026-06-30 11:00 EST

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

OGENOragenics2026-04-13 12:30 EST

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

NERVMinerva Neuroscience2026-03-25 20:05 EST

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

OGENOragenics2026-03-12 12:30 EST

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

KTTAPasithea Therapeutics2026-06-16 11:00 EST

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

View all latest news

Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, neurology, and endocrinology. Its commercial and development work centers on disorders with clear unmet need and durable treatment demand.

Recent company news

NBIXNeurocrine Biosciences2026-06-03 12:30 EST

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

NBIXNeurocrine Biosciences2026-05-18 20:05 EST

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

NBIXNeurocrine Biosciences2026-05-18 12:46 EST

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

NBIXNeurocrine Biosciences2026-05-06 12:30 EST

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Stock data

Close
176.41 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States